Search bioRxiv⌕ Search

Biology subjects

Fattet, L.

Publications and source records attributed to Fattet, L..

2 recordsLinked to original sources

Disordered N-terminal region of CLK1 oligomerizes for recruitment to nuclear substructures and splicing function

Cdc2-like kinase 1 (CLK1) phosphorylates the serine-arginine (SR) proteins, a family of nuclear factors essential for mRNA splicing. The ability of CLK1 to recognize and efficiently modify SR proteins is strictly dependent on a lengthy, disordered N-terminus flanking its kinase domain. In addition to stimulating phosphorylation, this 150-residue extension also induces large oligomer formation in CLK1 but it is unclear whether said structure is important for catalytic or cellular function. We identified a subset of N-terminal residues that, upon removal, impairs oligomerization of CLK1 but does not abolish phosphorylation of the SR protein SRSF1. Despite robust phosphorylation, CLK1 lacking these high-order oligomerization sequences cannot effectively enter nuclear speckles and release SRSF1. This inability to mobilize CLK1 has detrimental effects on the alternative splicing of the CLK1 gene, severing an important, autoregulatory mechanism that controls active cellular levels of the kinase. Such findings indicate that whereas a limited group of residues in the N-terminus activates the kinase domain for SR protein phosphorylation, sequences that induce oligomerization direct CLK1 to the proper subnuclear structures for splicing function.

biochemistry↗

Extracellular matrix rigidity controls breast cancer metastasis via TYK2-mediated mechanotransduction

Mechanical cues from the extracellular matrix (ECM) regulate various cellular processes. In breast cancer, increased tumor stiffness is associated with elevated metastasis risk and poor survival. We identify a unique role of the JAK family kinase TYK2 in suppressing breast cancer metastasis under low ECM stiffness. Genetic or pharmacological inhibition of TYK2 in mammary acini and patient-derived organoids leads to invasion at low ECM stiffness by promoting Epithelial-Mesenchymal Transition, which is independent of cytokine-induced JAK/STAT signaling. TYK2 blockade promotes metastasis in breast tumor cell- and patient-derived xenografts. TYK2 localizes at the plasma membrane via IFNAR1 association under low stiffness, but it becomes cytoplasmic and inactivated at high stiffness. Normal human breast epithelium displays membrane-localized TYK2, whereas invasive breast tumors exhibit cytoplasmic TYK2. These findings uncover a TYK2-dependent mechanism by which ECM rigidity suppresses breast cancer metastasis and underscore the need for vigilant breast cancer screening in patients receiving TYK2 inhibitors.

cancer biology↗